Search - tctmd.com

Displaying 1 - 20 of 33

Sort: Relevancy | Date

News Daily News

Even With Optimized GDMT, HFrEF Prognosis Remains Dire

Michael O'Riordan

January 30, 2026

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

News Daily News

HYPERION: Sotatercept Helps in PAH Even When Started Earlier in the Disease

Todd Neale

October 02, 2025

News Conference News ESC 2025

Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR

Michael O'Riordan

August 31, 2025

News Opinion Editor's Corner ESC 2025

What’s Going to Be Hot at ESC Congress 2025?

Michael O'Riordan

August 25, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

News Daily News

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Michael O'Riordan

May 07, 2024

News Daily News

Biologic Winrevair Wins FDA Approval for Treatment of PAH

L.A. McKeown

March 27, 2024

News Daily News

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

L.A. McKeown

August 31, 2023

News Daily News

Vast Majority of HFrEF Patients Eligible for Vericiguat

L.A. McKeown

February 08, 2023

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Daily News

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

Shelley Wood

May 27, 2021

News Daily News

FDA Approves Vericiguat for High-risk Patients With HF

Michael O'Riordan

January 20, 2021

News Daily News

Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors

Shelley Wood

September 30, 2020

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

News Conference News ACC 2020

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

Michael O'Riordan

March 28, 2020

News Daily News

VICTORIA Trial of Vericiguat for Worsening HF Meets Primary Endpoint

Todd Neale

November 20, 2019

Advertisement

Even With Optimized GDMT, HFrEF Prognosis Remains Dire

What’s Going to Be Hot at AHA 2025?

HYPERION: Sotatercept Helps in PAH Even When Started Earlier in the Disease

Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR

What’s Going to Be Hot at ESC Congress 2025?

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Biologic Winrevair Wins FDA Approval for Treatment of PAH

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

Vast Majority of HFrEF Patients Eligible for Vericiguat

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

FDA Approves Vericiguat for High-risk Patients With HF

Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

VICTORIA Trial of Vericiguat for Worsening HF Meets Primary Endpoint

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content